Pharma BD Deal Intelligence
Incyte adds subcutaneous delivery optionality to its lead mutCALR antibody
Full analysis, sources & comparables →Halozyme entered a global collaboration and license agreement with Incyte to evaluate additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms, using Halozyme's proprietary ENHANZE drug delivery technology. Halozyme receives an undisclosed upfront payment and is eligible for additional payments on achievement of agreed milestones. Incyte also secured an option to nominate up to two additional development targets using ENHANZE. Specific financial terms were not disclosed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Incyte Corporation / Halozyme Therapeutics, Inc. (this deal) | 2026 | — | 60 |
| Incyte Corporation / MacroGenics, Inc. | 2017 | $900M | 69 |
| Incyte Corporation / Vega Therapeutics, Inc. | 2026 | $2.0B | 68 |
| Incyte Corporation / Merus N.V. | 2017 | $3.0B | 35 |
| Incyte Corporation / Genesis Molecular AI, Inc. | 2026 | $1.0B | — |
| Incyte Corporation / Escient Pharmaceuticals Inc. | 2024 | $750M | — |
| Incyte Corporation / Calithera Biosciences, Inc. | 2017 | $803M | — |
← Browse all deals · How we score deals
More: 2026 deals · Incyte Corporation deals